Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng(Central South University), Michael R. Green(Harvard University), Runzhe Chen(The University of Texas MD Anderson Cancer Center), Sreejoyee Ghosh(The University of Texas MD Anderson Cancer Center), Man Chun John(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Neeraj Jain(The University of Texas MD Anderson Cancer Center), Haopeng Yang(Peking University), Luis Fayad(The University of Texas MD Anderson Cancer Center), Nahum Puebla‐Osorio(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Paolo Strati(The University of Texas MD Anderson Cancer Center), Guangchun Han(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Ryan Sun(The University of Texas MD Anderson Cancer Center), Hans C. Lee(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Jordan Showell(The University of Texas MD Anderson Cancer Center), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Sridevi Patchva(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Minghao Dang(The University of Texas MD Anderson Cancer Center), Frederick Hagemeister(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Shaojun Zhang(The University of Texas MD Anderson Cancer Center), Yuanxin Wang(The University of Texas MD Anderson Cancer Center), Enyu Dai(The University of Texas MD Anderson Cancer Center), Ruiping Wang(The University of Texas MD Anderson Cancer Center), Beth Chasen(The University of Texas MD Anderson Cancer Center)
Nature Medicine
October 5, 2020
10.1038/s41591-020-1061-7
Cited by 593

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
|Cell|2017|2.6k
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
|Nature|2010|1.6k
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
|Blood|2010|1.3k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k